Wolfe Research Initiates Coverage on Grail (NASDAQ:GRAL)

Wolfe Research started coverage on shares of Grail (NASDAQ:GRAL) in a research report released on Friday, Marketbeat Ratings reports. The firm issued a peer perform rating on the stock.

Separately, Guggenheim initiated coverage on Grail in a research note on Thursday, October 17th. They set a “neutral” rating on the stock.

Grail Stock Down 6.4 %

GRAL opened at $14.80 on Friday. Grail has a 1-year low of $12.33 and a 1-year high of $23.36. The business has a 50-day moving average of $13.82.

Insider Buying and Selling

In other Grail news, CEO Robert P. Ragusa sold 123,454 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the sale, the chief executive officer now directly owns 612,661 shares of the company’s stock, valued at approximately $8,589,507.22. This represents a 16.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Chun R. Ding purchased 7,629 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was acquired at an average cost of $13.52 per share, with a total value of $103,144.08. Following the completion of the acquisition, the insider now directly owns 3,503,655 shares in the company, valued at approximately $47,369,415.60. This trade represents a 0.22 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 58,829 shares of company stock worth $757,298 over the last ninety days.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.